Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Céline Bortolamiol"'
Autor:
Ulrich Mentzel, Markus Kramberg, Marc Iglarz, Enrico Vezzali, Frederic Trensz, Céline Bortolamiol, Daniel Wanner, Stephane Delahaye, Hakim Hadana, Daniel S. Strasser, Patrick Hess, Markus Rey, Joël Ménard, Martine Clozel
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 368:462-473
The endothelin (ET) system has emerged as a novel target for hypertension treatment where a medical need persists despite availability of several pharmacological classes, including renin angiotensin system (RAS) blockers. ET receptor antagonism has d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d32d8d86285b9758185f4b07108c406
https://doi.org/10.1124/jpet.118.253864
https://doi.org/10.1124/jpet.118.253864
Autor:
Enrico Vezzali, Magali Vercauteren, Manuela Schläpfer, Céline Bortolamiol, Stephane Delahaye, Edgar Weber, Hakim Hadana, Marc Iglarz, Kyle Landskroner, Markus Rey, Brian R. Whitby, Daniel Wanner, Patrick Hess, Oliver Nayler, Christophe Cattaneo, Diego Freti, Pauline Steiner, Martine Clozel, Rolf Studer, Bérengère Renault, Yasmina Bauer
Publikováno v:
Journal of Cardiovascular Pharmacology
Supplemental Digital Content Is Available in the Text.
Aims: We compared the efficacy of macitentan, a novel dual endothelin A/endothelin B receptor antagonist, with that of another dual endothelin receptor antagonist, bosentan, in a rat model o
Aims: We compared the efficacy of macitentan, a novel dual endothelin A/endothelin B receptor antagonist, with that of another dual endothelin receptor antagonist, bosentan, in a rat model o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbadfe07472519ec9813e1e3eeaaed66
https://pubmed.ncbi.nlm.nih.gov/26230396
https://pubmed.ncbi.nlm.nih.gov/26230396
Autor:
Marc Iglarz, Céline Bortolamiol, Daniel Wanner, Alexandre Bossu, Martine Clozel, Markus Rey, Patrick Hess
Publikováno v:
Life sciences. 118(2)
AimsThe endothelin (ET) system is a tissular system, as the production of ET isoforms is mostly autocrine or paracrine. Macitentan is a novel dual ETA/ETB receptor antagonist with enhanced tissue distribution and sustained receptor binding properties
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baf20fc2057a8956a996398799624f36
https://pubmed.ncbi.nlm.nih.gov/24582812
https://pubmed.ncbi.nlm.nih.gov/24582812